Press release

November 18, 2021

JCR Pharmaceuticals Co., Ltd.

Translation

Hyogo Work-life Balance Company Award Notice

JCR Pharmaceuticals Co., Ltd. (TSE 4552; President and Chairman: Shin Ashida; “JCR”) announced that it had received the Hyogo Work-Life Balance Company Award in fiscal year 2021.

This award is presented by the Hyogo Work-Life Center to companies and organizations that lead advanced initiatives to achieve a better work-life balance, such as the introduction of diverse work styles and the promotion of a work-life balance. So far, a total of 127 organizations have been awarded over 12 years.

JCR has been continually engaged in work style reforms. In 2020, she made a statement at the Hyogo Work-Life Center and achieved certification. Recently, JCR was evaluated in particular for the initiatives listed below, which resulted in the company receiving the award in fiscal year 2021.

[ JCR’s Evaluated Initiatives ]

Create a working environment where it is easy to balance childcare and work, based on a fundamental policy regardless of gender differences

??Establishment of in-house daycares and establishment of a system of subsidies for childcare for employees who cannot use the centers

??Engaged in initiatives such as a cafeteria space to support childcare and Ikuboss training (bosses supporting employees who raise children), and promoted the use of childcare leave by male employees

Going forward, JCR will actively undertake initiatives that promote work-style reforms and achieve a work-life balance to allow each member of the JCR team to actively and comfortably focus on their work and fully demonstrate their skills. individual capacities.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that is redefining expectations and expanding possibilities for people with rare and genetic diseases around the world. We continue to build on our 46-year heritage in Japan while expanding our

footprint in the United States, Europe and Latin America. We improve the lives of patients by applying our

unique scientific expertise and technologies to research, develop and deliver next-generation therapies. Our products approved in Japan include therapies for the treatment of growth disorders, Fabry disease, MPS II (Hunter syndrome), acute graft versus host disease and renal anemia. Our experimental products in development around the world are intended for the treatment of rare diseases

including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, Pompe disease, etc. JCR strives to expand opportunities for patients while accelerating medical advancements globally. Our core values ​​- reliability, trust and perseverance – benefit all of our stakeholders, including employees, partners and patients. Together we get high. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Caution Regarding Forward-Looking Statements

This document contains forward-looking statements which are subject to known and unknown risks and uncertainties, many of which are beyond our control. Forward-looking statements often contain words such as “believe”, “estimate”, “anticipate”, “intend”, “plan”, “will”, “should”, “target” and similar references to future periods. All forward-looking statements about our future plans, outlook, strategy and activities, financial performance and condition are based on judgments derived from information currently available to us. Factors or events that could cause our actual results to differ materially from those expressed in our forward-looking statements include, without limitation, a deterioration in economic conditions, a change in the legal or government system, a delay in the launch of a new product, impact on the pricing and product strategies of competitors, a decrease in the marketing capacity of our products, manufacturing difficulties or delays, a violation of our intellectual property rights, a court decision unfavorable in a major lawsuit and regulatory actions.

This document contains information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. In addition, it is intended to provide information about our company and our activities and not to solicit investments in securities that we issue.

Except as required by law, we assume no obligation to publicly update these forward-looking statements or to update factors that could cause actual results to differ materially, even if new information becomes available in the future. .

Contact:

Investors and media:

JCR Pharmaceuticals Co., Ltd. Corporate communications [email protected]

###

Disclaimer

JCR Pharmaceuticals Co. Ltd. published this content on November 18, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on November 18, 2021 08:01:03 AM UTC.